(Q38673161)

5 September 2017

1 reference

title

Cellular immunotherapy of cancer: an overview and future directions (English)

1 reference

5 September 2017

1 reference

3

Thomas E Ichim

1 reference

5 September 2017

Ziqi Tao

1

1 reference

5 September 2017

Shuang Li

2

1 reference

5 September 2017

Junbao Yang

4

1 reference

5 September 2017

Neil Riordan

5

1 reference

5 September 2017

Venkata Yenugonda

6

1 reference

5 September 2017

Ivan Babic

7

1 reference

5 September 2017

Santosh Kesari

8

1 reference

5 September 2017

1 June 2017

1 reference

5 September 2017

1 reference

5 September 2017

9

1 reference

5 September 2017

7

1 reference

5 September 2017

589-606

1 reference

Cancer immunotherapy: moving beyond current vaccines

5 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

The B7 and CD28 receptor families

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Cell biology of antigen processing in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Antigen presentation to naive CD4 T cells in the lymph node.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Progress in the treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8+T-Cell Function in Melanoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Dendritic cell vaccination in medullary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Use of interferon-alpha-induced dendritic cells in the therapy of patients with malignant brain gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: clinical trial protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate–pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Autologous dendritic cell vaccines for non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

The clinical experience with interleukin-2 in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Tumor infiltrating lymphocytes in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Genetic redirection of T cells for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Identification of two novel members of erbA superfamily by molecular cloning: the gene products of the two are highly related to each other

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Abnormal development of the locus coeruleus in Ear2(Nr2f6)-deficient mice impairs the functionality of the forebrain clock and affects nociception

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

The nuclear orphan receptor NR2F6 suppresses lymphocyte activation and T helper 17-dependent autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

AML1 interconnected pathways of leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Identification of a role for the nuclear receptor EAR-2 in the maintenance of clonogenic status within the leukemia cell hierarchy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

The orphan nuclear receptor EAR2 is overexpressed in colorectal cancer and it regulates survivability of colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Nuclear orphan receptor NR2F6 directly antagonizes NFAT and RORγt binding to the Il17a promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Transcription of Il17 and Il17f is controlled by conserved noncoding sequence 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Spontaneous Proliferation and Type 2 Cytokine Secretion by CD4+T Cells in Patients with Metastatic Melanoma Vaccinated with Antigen-Pulsed Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of d

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0086

21 January 2018

Identifiers

DOI

10.2217/IMT-2016-0086

1 reference

5 September 2017

1 reference